Filing Flows › Health Care › Lifeward (LFWD)
Lifeward (LFWD) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Lifeward (LFWD) Q2 2026 earnings results →
Q2 2026 Revenue up 16% year over year to $6.6M · 174¢ of every $1 of revenue lost · operating margin -62.7%
Lifeward made $6.6M in Q2 2026 (+16% Y/Y). Operating margin -62.7%, net loss $11.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $6.6M in Q2 2026, up 16% year over year and up 69% from the previous quarter.
Gross margin was 40.9%, down 3.0 points from Q2 2025. Operating costs exceeded revenue by $4.2M, an operating margin of -62.7%. Operating expenses fell 24% while revenue rose 16%. The fastest-growing cost line was Research & development (+129%). The quarter ended with a net loss of $11.5M, wider than the previous quarter's $10.8M loss. Net interest and other expense of $7.4M was the main reason.
Operating cash flow was −$6.0M. Non-cash charges added back $262K of share-based compensation. Working capital and other items added $5.3M. Capital expenditures of $8K exceeded it, leaving free cash flow of −$6.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $6.6M | +16% | -62.7% | −$11.5M | −$6.0M |
| Q1 2026 | 10-Q | May 20, 2026 | $3.9M | -22% | -263.5% | −$10.8M | −$3.7M |
| Q4 2025 | 10-K | Mar 18, 2026 | $5.1M | -33% | -100.7% | −$5.3M | −$3.6M |
| Q3 2025 | 10-Q | Nov 14, 2025 | $6.2M | +1% | -50.7% | −$3.2M | −$3.8M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $5.7M | -15% | -114.7% | −$6.6M | −$3.9M |
| Q1 2025 | 10-Q | May 15, 2025 | $5.0M | -5% | -96.4% | −$4.8M | −$5.5M |
| Q4 2024 | 10-K | Mar 7, 2025 | $7.5M | +10% | -201.8% | −$15.3M | −$4.0M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Lifeward
We are a medical device company that designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our initial product offerings were the ReWalk Personal and ReWalk Rehabilitation Exoskeleton devices for individuals with spinal cord injury (“SCI Products”). These devices are robotic exoskeletons that are designed for individuals with paraplegia that use our patented tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. These SCI Products allow individuals with spinal cord injury (“SCI”) the ability to stand and walk again during everyday activities at home or in the community.
In its own words, from its 10-K, filed Mar 18, 2026.
Lifeward against its Orthopedic, Prosthetic & Surgical Appliances & Supplies peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +16% against the peers' median +10%. Operating margin: -62.7% against the peers' median 16.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| LFWD Lifeward | Q2 2026 | $6.6M | +16% | -62.7% |
| ISRG Intuitive Surgical | Q3 2026 | $3.0B | +22% | 19.4% |
| ZBH Zimmer Biomet Holdings | Q3 2026 | $2.1B | +3% | 14.9% |
| EW Edwards Lifesciences | Q3 2026 | $1.7B | +10% | 17.4% |
| STE Steris | Q2 FY27 | $1.6B | +9% | 18.5% |
| ALGN Align Technology | Q3 2026 | $1.0B | +2% | 16.7% |
| ENOV Enovis | Q3 2026 | $559M | +2% | 0.6% |
| MSA MSA Safety | Q3 2026 | $536M | +14% | 16.4% |
| CDRE Cadre Holdings | Q3 2026 | $203M | +30% | 14.0% |
Source: Lifeward 10-Q on SEC EDGAR · CIK 1607962 · Orthopedic, Prosthetic & Surgical Appliances & Supplies
More on LFWD
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results